- Home
- MMI vs CVAC Comparison
MMI vs CVAC Comparison
Compare MMI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- CVAC
- Stock Information
- Founded
- MMI 1971
- CVAC 2000
- Country
- MMI United States
- CVAC Germany
- Employees
- MMI N/A
- CVAC N/A
- Industry
- MMI Real Estate
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- CVAC Health Care
- Exchange
- MMI Nasdaq
- CVAC Nasdaq
- Market Cap
- MMI 1.2B
- CVAC 1.2B
- IPO Year
- MMI 2013
- CVAC 2020
- Fundamental
- Price
- MMI $27.95
- CVAC $5.41
- Analyst Decision
- MMI Hold
- CVAC Hold
- Analyst Count
- MMI 1
- CVAC 3
- Target Price
- MMI N/A
- CVAC $6.83
- AVG Volume (30 Days)
- MMI 123.3K
- CVAC 404.4K
- Earning Date
- MMI 11-07-2025
- CVAC 11-11-2025
- Dividend Yield
- MMI 1.77%
- CVAC N/A
- EPS Growth
- MMI N/A
- CVAC N/A
- EPS
- MMI N/A
- CVAC 1.01
- Revenue
- MMI $725,903,000.00
- CVAC $599,540,810.00
- Revenue This Year
- MMI $9.50
- CVAC N/A
- Revenue Next Year
- MMI $17.73
- CVAC $23.83
- P/E Ratio
- MMI N/A
- CVAC $5.40
- Revenue Growth
- MMI 17.89
- CVAC 675.15
- 52 Week Low
- MMI $27.61
- CVAC $2.37
- 52 Week High
- MMI $42.80
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- MMI 26.76
- CVAC 53.41
- Support Level
- MMI $28.25
- CVAC $5.33
- Resistance Level
- MMI $29.38
- CVAC $5.45
- Average True Range (ATR)
- MMI 0.70
- CVAC 0.03
- MACD
- MMI -0.29
- CVAC 0.01
- Stochastic Oscillator
- MMI 6.22
- CVAC 66.10
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.